Business Context and Reporting Period
Tenaya Therapeutics, Inc. (TNYA) filed a Form 8-K on January 26, 2026, reporting two material events: a Nasdaq listing deficiency notice and an amendment to its equity incentive plan. The company is incorporated in Delaware and trades on the Nasdaq Global Select Market.
Key Financial Metrics
This filing is a current report and does not contain audited financial statements, revenue, profit, cash flow, or debt metrics. The only financial data point provided is the stock price performance triggering the listing notice:
- Stock Price Deficiency: The closing bid price of common stock was below $1.00 per share for 30 consecutive business days (December 12, 2025, through January 27, 2026).
Material Changes and Events
Nasdaq Listing Deficiency (Item 3.01)
On January 28, 2026, the company received notice from Nasdaq that it failed to meet the minimum bid price requirement of $1.00 per share under Listing Rule 5450(a)(1). The company has been granted a 180-day compliance period ending July 27, 2026, to regain compliance. To cure the deficiency, the stock must maintain a closing bid price of at least $1.00 for 10 consecutive business days during this period. Failure to comply may result in delisting or a transfer to the Nasdaq Capital Market, contingent on meeting other listing standards and potentially executing a reverse stock split.
Equity Plan Amendment (Item 5.02)
Effective January 26, 2026, the Board amended the 2024 Inducement Equity Incentive Plan to increase the share reserve by 2,161,000 shares, bringing the total aggregate reserve to 3,361,000 shares. This amendment was adopted without stockholder approval under Nasdaq rules. The plan is restricted to new hires or acquisitions and includes options, RSUs, and performance awards.
Outlook, Risks, and Management Commentary
Management intends to actively monitor the stock price and evaluate options to resolve the listing deficiency, though there is no assurance of regaining compliance. Risks include potential delisting if the minimum bid price is not sustained or if the company fails to qualify for a second compliance period. The filing explicitly states there can be no assurance that the company will maintain its listing on the Nasdaq Global Select Market.
Investor Verification Checklist
- Verify the current closing bid price of TNYA stock to assess progress toward the $1.00 threshold.
- Monitor for any announcements regarding a reverse stock split or transfer application to the Nasdaq Capital Market.
- Review the attached Exhibit 10.1 for specific terms of the amended Inducement Plan and potential dilution impact.
- Check for subsequent 8-K filings regarding the status of the compliance period or delisting notices.